QuickMedical® Launches Cellerate RX® from Wound Care Innovations
Pressure ulcers occur in approximately 9% of hospitalized patients, usually during the first 2 weeks of hospitalization. A study found that even with the use of a pressure-reducing bed and early nutritional support, 3% of patients in a surgical intensive care unit who were employed in the study developed pressure ulcers. The annual risk of pressure ulceration of patients with neurologic impairment is 5-8%, with a lifetime risk of approximately 85% and a mortality rate of 8%*.
Issaquah, WA (PRWEB) November 8, 2010
The prevalence of pressure ulcers among patients residing in long-term care facilities has been reported as 2.3-28% and has been an increasingly common reason for litigation. The presence of a pressure ulcer increases a nurse's workload by 50% for the patient and adds approximately $20,000 to the hospital bill. The treatment of pressure ulcers in the United States is estimated to cost more than $1 billion annually*.
"We are very excited to be offering the Cellerate RX® products from Wound Care Innovations," said Scott Hanna, CEO at QuickMedical®. "These products represent a true advancement in collagen based wound care products and I'm sure will exceed expectations of both the healthcare professional and their patients."
Jane Fore MD, Director, Tri-State Wound Care and Hyperbaric Center, Clarkston, Washington State said, "CellerateRX® is the standard of care in my clinic. This product is compatible with other wound care products and gives the wound environment the basic building blocks for growth and contributes an essential part of the wound matrix that supports the migration of cells to healing tissues."
According to the National Institute of Diabetes and Digestive and Kidney Diseases, an estimated 18 million Americans (6.3% of the population) are known to have diabetes, and millions more are considered to be at risk. Of those at risk, diabetes is undiagnosed in 5.2 million. Diabetic foot lesions are responsible for more hospitalizations than any other complication of diabetes. Among patients with diabetes, 15% will develop a foot ulcer, and 12-24% of those with a foot ulcer will require amputation. Indeed, diabetes is the leading cause of non-traumatic lower-extremity amputations in the United States, accounting for 60% of these amputations*.
Cathy Bradshaw, President of Wound Care Innovations said," 85% of all LEA (lower extremity amputations) are preceded by non-healing ulcerations. Our Cellerate RX® product has been shown to successfully address these diabetic wounds. Lower extremity wounds and the incidence of amputations is a serious issue in healthcare and we have a product that has been shown to provide quality outcomes in a cost effective manner."
CellerateRX® is FDA cleared for acute and chronic wounds which include but are not limited to: diabetic ulcers, venous stasis ulcers, ulcers due to arterial insufficiency, pressure ulcers stages I-IV, surgical wounds, traumatic wounds, superficial wounds, and 1st and 2nd degree burns. It is manufactured in the United States.
CellerateRX®'s patented activated collagen fragments are a fraction of the size of native collagen molecules, delivering the benefits of collagen to the body immediately. Manufactured in the USA. Apply 2-3 times per week. Type-1 bovine collagen.
About QuickMedical®:
Started in 1993, QuickMedical® is a national distributor of medical supplies and equipment. With offices and warehouse located in Issaquah, WA, QuickMedical® is able to provide nearly 16,000 medical products to choose from with the convenience of ordering directly by phone, fax or website. Many items are shipped within 24 hours. QuickMedical® is also a distributor for a number of manufacturers who offer their products via Premier, MedAssets, Amerinet, and other Group Purchasing Organization contracts. For government (GSA) pricing, call 888-345-4858.
About Wound Management Technologies, Inc. (WNDM):
Wound Management Technologies, Inc.'s primary focus is the distribution of its unique, patented collagen product, Cellerate RX®, in the $3.2B worldwide advanced wound care market, a market that is growing due to aging populations and the increase of diabetes. Over the past 2 years Wound Management has focused on developing evidenced-based studies on Cellerate RX® and gaining physician awareness by participation in key industry conferences. Now Wound Management is focused on expanding sales through partnerships and contracted independent representatives. Wound Management has other advanced biotech products in development for bone wax, bone void fillers and shingles pain reduction as well as a subsidiary focused on eHealth technology for secure healthcare data collaboration and storage. More information can be found on the company's web sites: http://www. wmgtech. com, http://www. celleraterx. com, and http://www. secureehealth. com. Wound Care Innovations, LLC, is a wholly owned subsidiary of WNDM.
*Source: Richard M Stillman, MD, FACS. Honorary Medical Staff, Northwest Medical Center; Former Chief of Staff and Medical Director, Wound Healing Center, Department of Surgery, Northwest Medical Center
# # #
